ReviewBiology2021
A Multifactorial Approach for Sarcopenia Assessment: A Literature Review.
Review in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review.Journal of translational medicine · 2025Pooled it
- Long-term impact of sarcopenia on functional decline and mortality in community-dwelling older adults: a systematic review and meta-analysis.Frontiers in nutrition · 2025Pooled it
- Food insecurity as a predictor of all-cause mortality and premature mortality among older adults: a longitudinal cohort analysis of ELSA study.Aging clinical and experimental research · 2026Article
- Article
- Tensiomyography-derived contractile parameters in sarcopenic and non-sarcopenic older adults.Frontiers in aging · 2026Article
- Article
- SarcoNet: A Pilot Study on Integrating Clinical and Kinematic Features for Sarcopenia Classification.Diagnostics (Basel, Switzerland) · 2025Article
- Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach.International journal of molecular sciences · 2025Review
- A Liposomal Strategy for Dual-Action Therapy in Sarcopenia: Co-Delivery of Caffeine and HAMA.International journal of molecular sciences · 2025Article
- Relationship between uric acid to high-density lipoprotein cholesterol ratio and sarcopenia in NHANES: exploring the mediating role of bilirubin and association with all-cause mortality.Frontiers in nutrition · 2025Article
- Strength training and sarcopenia-a mandatory link: focus on MicroRNAs.Frontiers in aging · 2025Review
- Using Flexible-Printed Piezoelectric Sensor Arrays to Measure Plantar Pressure during Walking for Sarcopenia Screening.Sensors (Basel, Switzerland) · 2024Article
- Dietary Protein and Physical Exercise for the Treatment of Sarcopenia.Clinics and practice · 2024Review
- Article
- Machine Learning Applications in Sarcopenia Detection and Management: A Comprehensive Survey.Healthcare (Basel, Switzerland) · 2023Article
- Association between Handgrip Strength, Skinfold Thickness, and Trunk Strength among University Students.Diagnostics (Basel, Switzerland) · 2023Article
- Ethical considerations in sarcopenia research.Journal of medical ethics and history of medicine · 2023Article
- Sarcopenia Transitions and Influencing Factors Among Chinese Older Adults With Multistate Markov Model.Innovation in aging · 2023Article
- Biomarkers of Frailty: miRNAs as Common Signatures of Impairment in Cognitive and Physical Domains.Biology · 2022Review
- Home-Based Physical Activity as a Healthy Aging Booster before and during COVID-19 Outbreak.International journal of environmental research and public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia refers to a progressive and generalized weakness of skeletal muscle as individuals age. Sarcopenia usually occurs after the age of 60 years and is associated with a persistent decline in muscle strength, function, and quality. A comparison of the risk factors associated with sarcopenia based on the European Working Group on Sarcopenia (1 and 2) in Older People, the Asian Working Group for Sarcopenia (1 and 2), the International Working Group on Sarcopenia, and the Foundation for the National Institutes of Health revealed no consistent patterns. Accordingly, the identification of a single risk factor for sarcopenia is unpredictable due to its "multifactorial" pathogenesis, with the involvement of a multitude of factors. Therefore, the first aim of this review was to outline and propose that the multiple factors associated with sarcopenia need to be considered in combination in the design of new experimentation in this area. A secondary aim was to highlight the biochemical risk factors that are already identified in subjects with sarcopenia to assist scientists in understanding the biology of the pathophysiological mechanisms affecting the old people with sarcopenia. We also briefly discuss primary outcomes (physical) and secondary outcomes (social and financial) of sarcopenia. For future investigative purposes, this comprehensive review may be useful in considering important risk factors in the utilization of a panel of biomarkers emanating from all pathways involved in the pathogenesis of this disease. This may help to establish a uniform consensus for screening and defining this disease. Considering the COVID-19 pandemic, its impact may be exacerbated in older populations, which requires immediate attention. Here, we briefly suggest strategies for advancing the development of smart technologies to deliver exercise in the COVID-19 era in an attempt regress the onset of sarcopenia. These strategies may also have an impact on sarcopenia's primary and secondary outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.